Yoshinaga Tsuneaki, Sekijima Yoshiki, Koyama Shingo, Maruyama Keiko, Yoshida Toshikazu, Kato Takeo, Ikeda Shu-ichi
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan.
Intern Med. 2014;53(23):2725-9. doi: 10.2169/internalmedicine.53.2996. Epub 2014 Dec 1.
We herein describe the case of a Japanese cerebrotendinous xanthomatosis (CTX) patient with a novel CYP27A1 gene mutation. The patient had been diagnosed with cataracts at 25 years of age and subsequently developed neurological symptoms in his forties, being referred to our hospital at 47 years of age. Upon admission, Achilles tendon xanthomas, cognitive impairment, dysphagia, dysarthria, dystonia, spasticity, muscle weakness and ataxia were observed. Brain MRI revealed abnormal signals in the dentate nuclei, periventricular white matter and pyramidal tract, and the serum cholestanol level was elevated. A CYP27A1 gene analysis identified compound heterozygosity for p.A335V, a novel mutation, and p.R405Q, a previously reported mutation. Making an early diagnosis of CTX is crucial, as the administration of chenodeoxycholic acid reverses metabolic derangement.
我们在此描述一例患有新型CYP27A1基因突变的日本脑腱黄瘤病(CTX)患者。该患者25岁时被诊断为白内障,随后在四十多岁时出现神经症状,47岁时转诊至我院。入院时,观察到跟腱黄瘤、认知障碍、吞咽困难、构音障碍、肌张力障碍、痉挛、肌肉无力和共济失调。脑部MRI显示齿状核、脑室周围白质和锥体束有异常信号,血清胆甾烷醇水平升高。CYP27A1基因分析确定为p.A335V(一种新型突变)和p.R405Q(一种先前报道的突变)的复合杂合性。由于鹅去氧胆酸的给药可逆转代谢紊乱,因此早期诊断CTX至关重要。